{"id":"fibroblast-growth-factor","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Edema"}]},"_chembl":{"chemblId":"CHEMBL4297954","moleculeType":"Unknown"},"_dailymed":{"setId":"c6beb454-5661-4d85-a6ba-b1971eda8965","title":"GUNA-FGF (FIBROBLAST GROWTH FACTOR) SOLUTION/ DROPS [GUNA SPA]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FGF is a naturally occurring signaling protein that activates fibroblast growth factor receptors (FGFRs) on the cell surface, triggering intracellular cascades that stimulate tissue repair, wound healing, and neovascularization. This mechanism is leveraged therapeutically to promote healing in damaged or ischemic tissues, particularly in wound care and tissue regeneration applications.","oneSentence":"Fibroblast growth factor (FGF) promotes cell proliferation, differentiation, and angiogenesis by binding to FGF receptors on target cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:30:09.657Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wound healing and tissue repair"},{"name":"Diabetic ulcers"}]},"trialDetails":[{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT04595747","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-03","conditions":"Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor","enrollment":48},{"nctId":"NCT07495579","phase":"PHASE2","title":"Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-04","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":146},{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT04083976","phase":"PHASE2","title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-20","conditions":"Advanced Solid Tumor","enrollment":316},{"nctId":"NCT07483684","phase":"PHASE3","title":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"HER2 IHC3+ Advanced Colorectal Cancer","enrollment":142},{"nctId":"NCT03390504","phase":"PHASE3","title":"A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-23","conditions":"Urothelial Cancer","enrollment":629},{"nctId":"NCT06164951","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia","status":"COMPLETED","sponsor":"QED Therapeutics, a BridgeBio company","startDate":"2023-11-10","conditions":"Achondroplasia","enrollment":114},{"nctId":"NCT05567185","phase":"PHASE1","title":"A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2023-03-03","conditions":"Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor","enrollment":5},{"nctId":"NCT04572295","phase":"PHASE1","title":"A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-09","conditions":"Breast Neoplasms","enrollment":51},{"nctId":"NCT07453290","phase":"","title":"Dysregulation of the Soluble α-Klotho-FGF23 Axis in Hashimoto's Thyroiditis: A Case-Control Study","status":"NOT_YET_RECRUITING","sponsor":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","startDate":"2026-03-02","conditions":"Autoimmune Thyroiditis","enrollment":150},{"nctId":"NCT04238715","phase":"PHASE2","title":"A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-01-22","conditions":"Cholangiocarcinoma","enrollment":63},{"nctId":"NCT06793709","phase":"","title":"A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy","status":"RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2025-07-10","conditions":"Biliary Tract Cancer","enrollment":60},{"nctId":"NCT07434843","phase":"PHASE2","title":"PH 2 Pemigatinib in SDH-deficient GIST","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-06","conditions":"SDH Gene Mutation, Gastrointestinal Stromal Tumor","enrollment":24},{"nctId":"NCT07424560","phase":"","title":"Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer","status":"RECRUITING","sponsor":"Zhilong Dong","startDate":"2026-02-25","conditions":"Bladder Cancer, Bladder Cancer Recurrence, Adjuvant Therapy for Bladder Cancer","enrollment":400},{"nctId":"NCT06625593","phase":"PHASE1","title":"A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-12-09","conditions":"Advanced Solid Tumor","enrollment":168},{"nctId":"NCT05052801","phase":"PHASE3","title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-03-07","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":547},{"nctId":"NCT06201533","phase":"NA","title":"Low-intensity Physical-cognitive Exercise and Cognitive Function","status":"RECRUITING","sponsor":"Chiang Mai University","startDate":"2024-04-07","conditions":"Mild Cognitive Impairment","enrollment":64},{"nctId":"NCT06851767","phase":"PHASE1, PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":"X-linked Severe Combined Immunodeficiency, X-SCID, XSCID","enrollment":18},{"nctId":"NCT07363135","phase":"NA","title":"Evaluation of Albumin Platelet-Rich Fibrin Following SRP in Patients With Periodontitis","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2024-11-20","conditions":"Periodontitis, Periodontitis (Stage 3)","enrollment":23},{"nctId":"NCT03651505","phase":"","title":"X-linked Hypophosphatemia Disease Monitoring Program","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2018-07-16","conditions":"X-linked Hypophosphatemia, Hypophosphatemic Rickets","enrollment":782},{"nctId":"NCT07169279","phase":"PHASE2","title":"Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)","status":"RECRUITING","sponsor":"QED Therapeutics, a BridgeBio company","startDate":"2025-11-19","conditions":"Achondroplasia","enrollment":77},{"nctId":"NCT07393373","phase":"PHASE2","title":"Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia","status":"ENROLLING_BY_INVITATION","sponsor":"QED Therapeutics, a BridgeBio company","startDate":"2026-04-21","conditions":"Hypochondroplasia","enrollment":135},{"nctId":"NCT05325866","phase":"PHASE1, PHASE2","title":"A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","status":"COMPLETED","sponsor":"Amgen","startDate":"2022-09-23","conditions":"Solid Tumors","enrollment":260},{"nctId":"NCT07292168","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1","status":"RECRUITING","sponsor":"Kidney Cancer Research Bureau","startDate":"2025-12-02","conditions":"Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic, Non-small Cell Lung Cancer Metastatic","enrollment":58},{"nctId":"NCT05544552","phase":"PHASE1, PHASE2","title":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tyra Biosciences, Inc","startDate":"2022-11-22","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor","enrollment":310},{"nctId":"NCT01746849","phase":"PHASE2","title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Leukemia, Multiple Myeloma, Myelodysplastic Syndrome","enrollment":82},{"nctId":"NCT06920043","phase":"PHASE2","title":"A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH","status":"RECRUITING","sponsor":"Boston Pharmaceuticals","startDate":"2025-04-09","conditions":"Metabolic Dysfunction-Associated Steatohepatitis","enrollment":42},{"nctId":"NCT06511648","phase":"PHASE2","title":"Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations","status":"RECRUITING","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2023-03-07","conditions":"Muscle-invasive Bladder Cancer","enrollment":90},{"nctId":"NCT07272395","phase":"","title":"Right Ventricular Function Changes After CIED Implantation: The RIGHT-CIED Study","status":"RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2025-08-15","conditions":"Right Ventricular Dysfunction","enrollment":40},{"nctId":"NCT04207086","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2020-11-11","conditions":"Melanoma Stage III","enrollment":21},{"nctId":"NCT06873035","phase":"PHASE2, PHASE3","title":"An Interventional Study of Infigratinib in Children With Hypochondroplasia","status":"ENROLLING_BY_INVITATION","sponsor":"QED Therapeutics, a BridgeBio company","startDate":"2025-04-22","conditions":"Hypochondroplasia","enrollment":24},{"nctId":"NCT04177004","phase":"PHASE1","title":"Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-04-30","conditions":"Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":53},{"nctId":"NCT04752293","phase":"","title":"Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-19","conditions":"Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction","enrollment":125},{"nctId":"NCT07271212","phase":"NA","title":"Scalp Care Efficacy Evaluation for Premium Revitalizing Elixir","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hungkuang University","startDate":"2025-11-01","conditions":"Scalp Health, Hair Condition, Hair Loss","enrollment":60},{"nctId":"NCT07271199","phase":"NA","title":"Eyelash Effect Evaluation for Premium Rejuvenation Eyelash Serum","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hungkuang University","startDate":"2025-11-01","conditions":"Skin Condition, Eyelash Growth, Eyelashes","enrollment":30},{"nctId":"NCT02307916","phase":"PHASE2","title":"Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations","status":"COMPLETED","sponsor":"D. Bradley Welling, MD, PhD","startDate":"2016-10","conditions":"Tympanic Membrane Perforation","enrollment":57},{"nctId":"NCT06448039","phase":"PHASE1, PHASE2","title":"In-office Repair of Chronic Tympanic Membrane Perforations","status":"SUSPENDED","sponsor":"D. Bradley Welling, MD, PhD","startDate":"2024-06-15","conditions":"Chronic Tympanic Membrane Perforation","enrollment":20},{"nctId":"NCT04960384","phase":"PHASE2","title":"Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2022-05-27","conditions":"Tympanic Membrane Perforation","enrollment":52},{"nctId":"NCT05052957","phase":"PHASE2","title":"hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2023-01-20","conditions":"Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma","enrollment":16},{"nctId":"NCT03011372","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-04-25","conditions":"MPN (Myeloproliferative Neoplasms)","enrollment":47},{"nctId":"NCT06073808","phase":"NA","title":"The Role of Amnion Membrane Allografts in Nipple Preservation","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-01-01","conditions":"Mastectomy, Gender Affirmation Surgery, Nipple Sparing Mastectomy","enrollment":30},{"nctId":"NCT03797326","phase":"PHASE2","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-02-12","conditions":"Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer","enrollment":611},{"nctId":"NCT04024436","phase":"PHASE2","title":"A Study of TAS-120 in Patients With Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2020-01-28","conditions":"Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification","enrollment":64},{"nctId":"NCT04003610","phase":"PHASE2","title":"Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2020-05-14","conditions":"Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":7},{"nctId":"NCT03822117","phase":"PHASE2","title":"Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-10-17","conditions":"Solid Tumor Malignancy","enrollment":111},{"nctId":"NCT05145010","phase":"PHASE2","title":"Extension Study of Infigratinib in Children With Achondroplasia (ACH)","status":"ENROLLING_BY_INVITATION","sponsor":"QED Therapeutics, a BridgeBio company","startDate":"2021-12-06","conditions":"Achondroplasia","enrollment":300},{"nctId":"NCT04265651","phase":"PHASE2","title":"Study of Infigratinib in Children With Achondroplasia","status":"COMPLETED","sponsor":"QED Therapeutics, a BridgeBio company","startDate":"2020-03-10","conditions":"Achondroplasia","enrollment":84},{"nctId":"NCT03144661","phase":"PHASE1","title":"An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2017-05-25","conditions":"Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer","enrollment":25},{"nctId":"NCT05120726","phase":"PHASE4","title":"A Novel Therapeutic Treatment of Pyoderma Gangrenosum","status":"TERMINATED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2021-06-02","conditions":"Pyoderma Gangrenosum","enrollment":5},{"nctId":"NCT06410976","phase":"","title":"Prospective Clinical Assessment Study in Children With Hypochondroplasia","status":"RECRUITING","sponsor":"QED Therapeutics, a BridgeBio company","startDate":"2024-06-05","conditions":"Hypochondroplasia","enrollment":150},{"nctId":"NCT04962867","phase":"PHASE2","title":"NCCH2006/MK010 Trial (FORTUNE Trial)","status":"RECRUITING","sponsor":"National Cancer Center, Japan","startDate":"2021-06-15","conditions":"Advanced or Recurrent Solid Tumors, FGFR Gene Alterations","enrollment":75},{"nctId":"NCT07131943","phase":"NA","title":"Radiofrequency vs. Ultrasound Therapy for Shoulder Joint in Stroke Patients: A Comparative Clinical Trial","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-09-28","conditions":"Stroke ( 3 Months After Onset), Stroke in Patients: New Tool to Evaluate the Impact in Their Life","enrollment":45},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT02490501","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects","status":"COMPLETED","sponsor":"BioArctic AB","startDate":"2015-06","conditions":"Spinal Cord Injury","enrollment":10},{"nctId":"NCT06328166","phase":"NA","title":"The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2024-03-22","conditions":"Carpal Tunnel Syndrome","enrollment":24},{"nctId":"NCT06418295","phase":"","title":"Cytokine Alterations and Chronic Post-Surgical Pain","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2026-01-01","conditions":"Chronic Post Operative Pain","enrollment":60},{"nctId":"NCT06389799","phase":"PHASE2","title":"A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)","status":"RECRUITING","sponsor":"Lund University Hospital","startDate":"2024-06-20","conditions":"Dedifferentiated Liposarcoma","enrollment":33},{"nctId":"NCT06985121","phase":"NA","title":"Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence","status":"COMPLETED","sponsor":"Hungkuang University","startDate":"2025-04-08","conditions":"Scalp Health, Hair Condition, Hair Loss","enrollment":60},{"nctId":"NCT03656536","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-06-03","conditions":"Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma","enrollment":167},{"nctId":"NCT02872714","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-01-12","conditions":"UC (Urothelial Cancer)","enrollment":263},{"nctId":"NCT02924376","phase":"PHASE2","title":"Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-01-16","conditions":"Cholangiocarcinoma","enrollment":147},{"nctId":"NCT07113418","phase":"","title":"Role of FGF21 in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-09","conditions":"Breast Cancer","enrollment":84},{"nctId":"NCT06668831","phase":"","title":"Fibroblast Growth Factor 23 and Risk of Cardiac Arrhythmias in Hemodialysis Patients","status":"RECRUITING","sponsor":"Antonio Bellasi","startDate":"2024-10-12","conditions":"Hemodialysis","enrollment":30},{"nctId":"NCT05253807","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2022-04-29","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":8},{"nctId":"NCT05139004","phase":"PHASE1","title":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-19","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":7},{"nctId":"NCT06905054","phase":"PHASE2","title":"Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-15","conditions":"Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC","enrollment":80},{"nctId":"NCT06664684","phase":"NA","title":"Intermittent Fasting and Metabolic Dysfunction Associated Fatty Liver Disease","status":"COMPLETED","sponsor":"Istanbul Bilgi University","startDate":"2022-05-23","conditions":"Intermittent Fasting, Metabolic Dysfunction-Associated Fatty Liver Disease","enrollment":55},{"nctId":"NCT03825484","phase":"","title":"Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options","status":"APPROVED_FOR_MARKETING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"","conditions":"Advanced Cancers and FGFR Genetic Alterations","enrollment":""},{"nctId":"NCT06986382","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-07","conditions":"Crohn Disease","enrollment":14},{"nctId":"NCT06929195","phase":"PHASE1","title":"Clinical Trial to Evaluate the Tolerance of TQB2210 Injection","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-05-16","conditions":"Advanced Malignant Tumours","enrollment":90},{"nctId":"NCT05404061","phase":"NA","title":"The Poor Responders Study","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2018-08-01","conditions":"Bariatric Surgery Candidate, Obesity, Morbid, Diabetes Mellitus, Type 2","enrollment":220},{"nctId":"NCT02699606","phase":"PHASE2","title":"A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-07-08","conditions":"Neoplasm","enrollment":35},{"nctId":"NCT03324373","phase":"PHASE1","title":"Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Yousef Zakharia","startDate":"2019-03-20","conditions":"Renal Cell Carcinoma","enrollment":11},{"nctId":"NCT04035811","phase":"","title":"Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"QED Therapeutics, a BridgeBio company","startDate":"2019-08-12","conditions":"Achondroplasia","enrollment":271},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT02052778","phase":"PHASE1, PHASE2","title":"A Study of TAS-120 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2014-07-21","conditions":"Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors","enrollment":407},{"nctId":"NCT02404870","phase":"PHASE1","title":"Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-09-16","conditions":"Healthy Volunteers","enrollment":67},{"nctId":"NCT06842810","phase":"","title":"Fibroblast Growth Factor 21 in Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-05-01","conditions":"Systemic Lupus Erthematosus","enrollment":95},{"nctId":"NCT06837558","phase":"","title":"Predictors of Bone Mineral Density in Lupus Nephritis Activity","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-04-01","conditions":"Bone Mineral Density and Lupus Nephritis Activity","enrollment":100},{"nctId":"NCT06806319","phase":"PHASE2","title":"Assessment of Growth Factors Levels Associated with Wound Healing After Soft Tissue Crown Lengthening","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2021-10-03","conditions":"Gingival Overgrowth","enrollment":80},{"nctId":"NCT01703481","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06-15","conditions":"Tumor or Lymphoma","enrollment":188},{"nctId":"NCT02421185","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05-25","conditions":"Carcinoma, Hepatocellular","enrollment":53},{"nctId":"NCT02243852","phase":"","title":"Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)","status":"WITHDRAWN","sponsor":"University of Liverpool","startDate":"2014-09","conditions":"Growth Hormone Deficiency","enrollment":""},{"nctId":"NCT04232033","phase":"NA","title":"The Physiological Effects of FGF21 on Alcohol Preference and Glucose Metabolism","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2021-05-01","conditions":"Fibroblast Growth Factor 21, Tast Perference","enrollment":20},{"nctId":"NCT06632262","phase":"PHASE2","title":"A Phase 2 Clinical Study of ABSK061 and ABSK043","status":"RECRUITING","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2024-11-13","conditions":"HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer","enrollment":202},{"nctId":"NCT02038673","phase":"PHASE1","title":"An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-11-05","conditions":"Solid Tumors","enrollment":86},{"nctId":"NCT06160752","phase":"PHASE1","title":"Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations","status":"RECRUITING","sponsor":"Tyra Biosciences, Inc","startDate":"2023-11-22","conditions":"Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor","enrollment":40},{"nctId":"NCT06607198","phase":"","title":"Clinical-pathological Evaluation of Pit-NETs","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-10-01","conditions":"Pituitary, Cancer, Neuroendocrine Tumors","enrollment":940},{"nctId":"NCT06577376","phase":"PHASE1, PHASE2","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-08-26","conditions":"Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past","enrollment":252},{"nctId":"NCT06331169","phase":"PHASE1","title":"Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-07-31","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT06206278","phase":"PHASE2","title":"Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma","status":"TERMINATED","sponsor":"LianBio LLC","startDate":"2023-10-19","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":6},{"nctId":"NCT02053636","phase":"PHASE2","title":"A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2013-12","conditions":"Breast Cancer","enrollment":76},{"nctId":"NCT06516939","phase":"NA","title":"The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin","status":"RECRUITING","sponsor":"Shanghai Dermatology Hospital","startDate":"2024-06-10","conditions":"Sensitive Skin","enrollment":28},{"nctId":"NCT05545969","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma","status":"WITHDRAWN","sponsor":"Melanoma Institute Australia","startDate":"2024-03","conditions":"Mucosal Melanoma","enrollment":""},{"nctId":"NCT02537431","phase":"PHASE3","title":"Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2015-12-23","conditions":"X-linked Hypophosphatemia","enrollment":14},{"nctId":"NCT03866148","phase":"NA","title":"Obstructive Sleep Apnoea and Cardiac Arrhythmias","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospitals Coventry and Warwickshire NHS Trust","startDate":"2019-10-03","conditions":"Obstructive Sleep Apnea, Cardiovascular Diseases, Arrhythmia","enrollment":200},{"nctId":"NCT02526160","phase":"PHASE3","title":"Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2015-10-22","conditions":"X-linked Hypophosphatemia","enrollment":134},{"nctId":"NCT04625907","phase":"PHASE1, PHASE2","title":"FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2020-09-17","conditions":"Rhabdomyosarcoma","enrollment":1672}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44859,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"fibroblast growth factor","genericName":"fibroblast growth factor","companyName":"Chinese PLA General Hospital","companyId":"chinese-pla-general-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Fibroblast growth factor (FGF) promotes cell proliferation, differentiation, and angiogenesis by binding to FGF receptors on target cells. Used for Wound healing and tissue repair, Diabetic ulcers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}